行情

CELG

新基医药
CELG
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
19.84
4.606
6.37
77,001,936,000.00
关于 CELG
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
展开

CELG 新闻

更多
科、创两板新基潮涌:注册制改革备战资金箭在弦上
和讯 · 5天前
The No. 1 Pharma Stock Just Crushed Earnings Views — Is BMY Stock A Buy?
Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
Investor's Business Daily · 5天前
Legend Biotech Seeks U.S. Capital For Pipeline Advance
Seeking Alpha - Article · 6天前
百济神州财报:挡不住烧钱的火
界面新闻 · 05/15 14:32
新基来袭:投资养老两不误,年轻人也需要的养老FOF!
长城基金微天地 · 05/14 06:23
百济神州公布2020年第一季度财务业绩
新浪网 · 05/11 20:05
ADC Therapeutics Cuts Price In 2nd IPO Attempt
Seeking Alpha - Article · 05/11 16:29
多领域布局稳健出基 鹏华基金袁航新基5月18日发行
和讯网 · 05/06 03:00

热门股票

代码
价格
涨跌幅

微牛提供新基医药(NASDAQ-CELG)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CELG股票新闻,以帮助您做出投资决策。